Polymeric anticancer drugs with pH-controlled activation

Advanced Drug Delivery Reviews

Volumn 56, Issue 7, 2004, Pages 1023-1050

  Ulbrich, Karel ^a   Šubr, Vladimír ^a  

^a INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

4 aminobenzoyl; 6 aminohexanoyl; AB; Acid sensitive; AH; Boc; Cancer; Dau; Daunomycin; DDS; Dox; Doxorubicin; Drug carriers; Drug delivery; Drug delivery systems; Drug release; Drug targeting; EPR; pH sensitivity; Polymer prodrugs; Tert butyloxycarbonyl

Indexed keywords

ANTIBODIES; CONTROLLED DRUG DELIVERY; MACROMOLECULES; ONCOLOGY; PH EFFECTS; POLYMERS; TUMORS;

ACID-SENSITIVE SPACERS; CANCER THERAPY; POLYMER-DRUG CONJUGATES;

DRUG PRODUCTS;

2,6 DIAMINOPURINE 9 (2 DEOXY 2,2 DIFLUORORIBOSIDE); ALGINIC ACID; ANTHRACYCLINE DERIVATIVE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; CAELY; CARBOXYMETHYLCELLULOSE; CHITOSAN; CHLORAMBUCIL; DAUNORUBICIN; DENDRIMER; DEXTRAN; DOXORUBICIN; DRUG CARRIER; HUMAN SERUM ALBUMIN; HYDRAZIDE DERIVATIVE; HYDRAZONE DERIVATIVE; INULIN; MACROGOL DERIVATIVE; MITOMYCIN C; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; POLY DEXTRO LYSINE; POLYACRYLAMIDE; POLYAMINOACID; POLYGLUTAMIC ACID; POLYMER; POLYSACCHARIDE; PULLULAN; TRANSFERRIN; UNINDEXED DRUG; VINYL DERIVATIVE;

ACID TOLERANCE; ACIDITY; ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BLADDER CANCER; BLOOD VESSEL PERMEABILITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; COLON CANCER; COLORECTAL CARCINOMA; CONTROLLED DRUG RELEASE; DRUG ACTIVATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG EFFECT; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; EXTRACELLULAR FLUID; HUMAN; IMMUNOGENICITY; INTERNALIZATION; KIDNEY CARCINOMA; LEUKEMIA P 388; LUNG CANCER; LUNG METASTASIS; LYSOSOME; MACROMOLECULE; MELANOMA; MICELLE; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; TREATMENT OUTCOME; TUMOR; TUMOR VASCULARIZATION;

EID: 1942438684     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.10.040     Document Type: Article

References (146)

1. Han S.K., Na K., Bae Y.H. Sulfonamide based pH-sensitive polymeric micelles: physicochemical characteristics and pH-dependent aggregation. Colloids Surf., A. 214:2003;49-59.
2. Kataoka K., Matsumoto T., Yokoyama M., Okano T., Sakurai Y., Fukushima S., Okamoto K., Kwon G.S. Doxorubicin-loaded poly(ethylene glycol)-poly(β- benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control. Release. 64:2000;143-153.
3. Yasugi K., Nagasaki Y., Kato M., Kataoka K. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L- lactide) block copolymers as potential drug carrier. J. Control. Release. 62:1999;89-100.
4. Kohori F., Sakai K., Aoyagi T., Yokoyama M., Sakurai Y., Okano T. Preparation and characterization of thermally responsive block copolymer micelles comprising poly(N-isopropylacrylamide-b-DL-lactide. J. Control. Release. 55:1998;87-98.
5. Kataoka K., Kwon G.S., Yokoyama M., Okano T., Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J. Control. Release. 24:1993;119-132.
6. Yokoyama M., Miyauchi M., Yamada N., Okano T., Sakurai Y., Kataoka K., Inoue S. Polymer micelles as novel drug carrier: adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J. Control. Release. 11:1990;269-278.
7. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47:2001;113-131.
8. Fontana G., Licciardi M., Mansueto S., Schillaci D., Giammona G. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials. 22:2001;2857-2865.
9. Verrecchia T., Spenlehauer G., Bazile D.V., Murry-Brelier A., Archimbaud Y., Veillard M. Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J. Control. Release. 36:1995;49-61.
10. Stearne L.E.T., Schiffelers R.M., Smouter E., Bakker-Woudenberg I.A.J.M., Gyssens I.C. Biodistribution of long-circulating PEG-liposomes in a murine model of established subcutaneous abscesses. BBA, Biomembranes. 1561:2002;91-97.
11. Carrion C., Domingo J.C., de Madariaga M.A. Preparation of long-circulating immunoliposomes using PEG-cholesterol conjugates: effect of the spacer arm between PEG and cholesterol on liposomal characteristics. Chem. Phys. Lipids. 113:2001;97-110.
12. Gabizon A., Goren D., Cohen R., Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Control. Release. 53:1998;275-279.
13. Sadzuka Y., Hirota S. Physical properties and tissue distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes. Adv. Drug Deliv. Rev. 24:1997;257-263.
14. Gabizon A., Goren D., Horowitz A.T., Tzemach D., Lossos A., Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev. 24:1997;337-344.
15. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., Searle F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release. 74:2001;135-146.
16. Satchi R., Connors T.A., Duncan R. PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer. 85:2001;1070-1076.
17. Satchi-Fainaro R., Wrasidlo W., Lode H.N., Shabat D. Synthesis and characterization of a catalytic antibody-HPMA copolymer-conjugate as a tool for tumor selective prodrug activation. Bioorg. Med. Chem. 10:2002;3023-3029.
18. Li C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 54:2002;695-713.
19. Christie R.J., Grainger D.W. Design strategies to improve soluble macromolecular delivery constructs. Adv. Drug Deliv. Rev. 55:2003;421-437.
20. Lu Z.R., Shiah J.G., Sakuma S., Kopečková P., Kopeček J. Design of novel bioconjugates for targeted drug delivery. J. Control. Release. 78:2002;165-173.
21. Ulbrich K., Šubr V., Strohalm J., Plocová D., Jelínková M., Říhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation. J. Control. Release. 64:2000;63-79.
22. Říhová B., Jelínková M., Strohalm J., Šubr V., Plocová D., Hovorka O., Novák M., Plundrová D., Germano Y., Ulbrich K. Polymeric drugs based on conjugates of synthetic and natural macromolecules: II. Anti-cancer activity of antibody or (Fab')2-targeted conjugates and combined therapy with immunomodulators. J. Control. Release. 64:2000;241-261.
23. Putnam D., Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
24. Garnett M.C. Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev. 53:2001;171-216.
25. Dubowchik G.M., Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83:1999;67-123.
26. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell. 3:2003;207-212.
27. Trail P.A., Bianchi A.B. Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 11:1999;584-588.
28. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer. 2:2002;750-763.
29. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2:2003;347-360.
30. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2:2003;214-221.
31. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
32. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41:2001;189-207.
33. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., Duncan R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer. 31:1995;766-770.
34. Maeda H., Fang J., Inutsuka T., Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3:2003;319-328.
35. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 65:2000;271-284.
36. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 3:1992;351-362.
37. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release. 74:2001;47-61.
38. Takakura Y., Hashida M. Macromolecular drug carrier systems in cancer-chemotherapy-macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18:1995;207-231.
39. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Walter P. Molecular Biology of the Cell. 4th ed. 2002;Taylor & Francis Group, London.
40. Kovář M., Strohalm J., Etrych T., Ulbrich K., Říhová B. Star structure of antibody-targeted HPMA copolymer-bound doxoribicin: a novel type of polymeric conjugate for targeted drug delivery with potent anti-tumor effect. Bioconjug. Chem. 13:2002;206-215.
41. Rejmanová P., Kopeček J., Pohl J., Baudyš M., Kostka V. Polymers containing enzymatically degradable bonds 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:1983;2009-2020.
42. Tang A.J., Kopečková P., Kopeček J. Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes. Pharm. Res. 20:2003;360-367.
43. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
44. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov. Today. 7:2002;1138-1143.
45. Hallahan D., Geng L., Qu S.M., Scarfone C., Giorgio T., Donnelly E., Gao X., Clanton J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell. 3:2003;63-74.
46. Hallahan D.E., Geng L., Cmelak A.J., Chakravarthy A.B., Martin W., Scarfone C., Gonzalez A. Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature. J. Control. Release. 74:2001;183-191.
47. Arap W., Haedicke W., Bernasconi M., Kain R., Rajotte D., Krajewski S., Ellerby H.M., Bredesen D.E., Pasqualini R., Ruoslahti E. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA. 99:2002;1527-1531.
48. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60:2000;722-727.
49. Shadidi M., Sioud M. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J. 16:2002;U478-U494.
50. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci., Polym. Symp. 51:1975;135-153.
51. Hashida M., Takakura Y., Matsumoto S., Sasaki H., Kato A., Kojima T., Muranishi S., Sezaki H. Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Chem. Pharm. Bull. 31:1983;2055-2063.
52. Duncan R., Spreafico F. Polymer conjugates - pharmacokinetic considerations for design and development. Clin. Phamacokinet. 27:1994;290-306.
53. Hoste K., Schacht E.H., Seymour L.W. New derivatives of polyglutamic acid as drug carrier systems. J. Control. Release. 64:2000;53-61.
54. Sakuma S., Lu Z.R., Pecharová B., Kopečková P., Kopeček J. N-(2-hydroxypropyl)-methacrylamide copolymer-9- aminocamptothecin conjugate: colon-specific drug delivery in rats. J. Bioact. Compat. Polym. 17:2002;305-319.
55. Searle F., Gac-Breton S., Keane R., Dimitrijevic S., Brocchini S., Sausville E.A., Duncan R. N-(2-hydroxypropyl)methacrylamide copolymer-6-(3- aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation. Bioconjug. Chem. 12:2001;711-718.
56. 5-(2- hydroxyethyl-L-glutamine)] as carrier for macromolecular prodrugs. J. Control. Release. 72:2001;257.
57. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin. Cancer Res. 5:1999;83-94.
58. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin C.M., Doran J., David M., Anderson D., Christodoulou C., Young A.M. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Control. Release. 57:1999;281-290.
59. Hopewell J.W., Duncan R., Wilding D., Chakrabarti K. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin- galactosamine conjugate antitumour agent. Hum. Exp. Toxicol. 20:2001;461-470.
60. Říhová B., Strohalm J., Kubáč ková K., Jelínková M., Rozprimová L., Šírová M., Plocová D., Mrkvan T., Kovář M., Pokorná J., Etrych T., Ulbrich K. Drug-HPMA-HuIg conjugates effective against human solid cancer. Adv. Exp. Med. Biol. 519:2003;125-143.
61. Rogers K.E., Tokes Z.A. Novel mode of cytotoxicity obtained by coupling inactive anthracycline to a polymer. Biochem. Pharmacol. 33:1984;605-608.
62. Rogers K.E., Carr B.I., Tokes Z.A. Cell surface-mediated cyto-toxicity of polymer-bound adriamycin against drug-resistant hepatocytes. Cancer Res. 43:1983;2741-2748.
63. Kopeček J. Controlled biodegradability of polymers - a key to drug delivery systems. Biomaterials. 5:1984;19-25.
64. Soyez H., Schacht E., Vanderkerken S. The crucial role of spacer groups in macromolecular prodrug design. Adv. Drug Deliv. Rev. 21:1996;81-106.
65. Takakura Y., Matsumoto S., Hashida M., Sezaki H. Physicochemical properties and antitumor activities of polymeric prodrugs of mitomycin C with different regeneration rates. J. Control. Release. 10:1989;97-105.
66. Gerweck L.E., Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 56:1996;1194-1198.
67. Volk T., Jahde E., Fortmeyer H.P., Glusenkamp K.H., Rajewsky M.F. pH in human tumor xenografts - effect of intravenous administration of glucose. Br. J. Cancer. 68:1993;492-500.
68. Kratz F., Beyer U., Schutte M.T. Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carrier Syst. 16:1999;245-288.
69. Roth T., Kratz F., Steidle C., Unger C., Fiebig H.H. In vitro and in vivo antitumor efficacy of acid sensitive albumin and poly(ethylene) glycol conjugates of doxorubicin. Ann. Oncol. 9:1998;102.
70. Etrych T., Chytil P., Jelínková M., Ríhová B., Ulbrich K. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity. Macromol. Biosci. 2:2002;43-52.
71. Etrych T., Jelínková M., Říhová B., Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release. 73:2001;89-102.
72. Říhová B., Etrych T., Pechar M., Jelínková M., Št'astný M., Hovorka O., Kovář M., Ulbrich K. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J. Control. Release. 74:2001;225-232.
73. Ulbrich K., Etrych T., Chytil P., Jelínková M., Říhová B. HPMA copolymers with pH-controlled release of doxorubicin. In vitro cytotoxicity and in vivo antitumor activity. J. Control. Release. 87:2003;33-47.
74. Hudecz F., Clegg J.A., Kajtar J., Embleton M.J., Szekerke M., Baldwin R.W. Synthesis, conformation, biodistribution, and in vitro cytotoxicity of daunomycin branched polypeptide conjugates. Bioconjug. Chem. 3:1992;49-57.
75. Choi W.M., Kopečková P., Minko T., Kopeček J. Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells. J. Bioact. Compat. Polym. 14:1999;447-456.
76. Shen W.C., Ryser H.J.P. cis-Aconityl spacer between daunomycin and macromolecular carriers - a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 102:1981;1048-1054.
77. Hurwitz E., Wilchek M., Pitha J. Soluble macromolecules as carriers for daunorubicin. J. Appl. Biochem. 2:1980;25-35.
78. Kruger M., Beyer U., Schumacher P., Unger C., Zahn H., Kratz F. Synthesis and stability of four maleimide derivatives of the anticancer drug doxorubicin for the preparation of chemoimmunoconjugates. Chem. Pharm. Bull. 45:1997;399-401.
79. Kratz F., Beyer U., Collery P., Lechenault F., Cazabat A., Schumacher P., Falken U., Unger C. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin. Biol. Pharm. Bull. 21:1998;56-61.
80. Kratz F., Beyer U., Schumacher P., Kruger M., Zahn H., Roth T., Fiebig H.H., Unger C. Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates. Bioorg. Med. Chem. Lett. 7:1997;617-622.
81. Kratz F., Fichtner I., Beyer U., Schumacher P., Roth T., Fiebig H.H., Unger C. Antitumour activity of acid labile transferrin and albumin doxorubicin conjugates in in vitro and in vivo human tumour xenograft models. Eur. J. Cancer. 33:1997;784.
82. Roth, T., Fiebig, H.H., Eckert, C., Spitzmüller, B., Beyer, U., Schumacher, P., Unger, C., Kratz, F., In vitro antitumor efficacy of acid-labile transferrin conjugates of doxorubicin in ten human xenografts, Proc. Am. Assoc. Cancer Res. 38 1997, S433, 2898.
83. Drevs J., Hofmann I., Marme D., Unger C., Kratz F. In vivo and in vitro efficacy of an acid-sensitive albumin conjugate of adriamycin compared to the parent compound in murine renal-cell carcinoma. Drug Deliv. 6:1999;89-95.
84. Rodrigues P.C.A., Schumacher P., Roth T., Fiebig H.H., Unger C., Mülhaupt R., Kratz F. Structure-activity relationships of novel polyethylene glycol conjugates (MW 20,000 and 70,000) of the antitumor drug daunomycin. 3rd International Symposium on Polymer Therapeutics, London:1998.
85. Fichtner I., Beyer U., Falken U., Meyer G., Schumacher P., Unger C., Kratz F. Efficacy of acid labile transferrin and albumin doxorubicin conjugates in in vitro and in vivo breast carcinoma systems. 2nd International Symposium on Polymer Therapeutics, Kumamoto, Japan:1997.
86. Beyer U., Rothen-Rutishauser B., Unger C., Wunderli-Allenspach H., Kratz F. Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. Pharm. Res. 18:2001;29-38.
87. Beyer U., Roth T., Schumacher P., Maier G., Unold A., Frahm A.W., Fiebig H.H., Unger C., Kratz F. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil. J. Med. Chem. 41:1998;2701-2708.
88. Kratz F., Beyer U., Roth T., Schutte M.T., Unold A., Fiebig H.H., Unger C. Albumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in vitro efficacy. Arch. Pharm. 331:1998;47-53.
89. Coessens V., Schacht E., Domurado D. Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage. J. Control. Release. 38:1996;141-150.
90. Alshamkhani A., Duncan R. Synthesis, controlled-release properties and antitumor-activity of alginate-cis-aconityl-daunomycin conjugates. Int. J. Pharm. 122:1995;107-119.
91. Zunino F., Pratesi G., Micheloni A. Poly(carboxylic acid) polymers as carriers for anthracyclines. J. Control. Release. 10:1989;65-73.
92. De Marre A., Seymour L.W., Schacht E. Evaluation of the hydrolytic and enzymatic stability of macromolecular mitomycin C derivatives. J. Control. Release. 31:1994;89-97.
93. Akamatsu K., Yamasaki Y., Nishikawa M., Takakura Y., Hashida M. Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E1 using lactosylated poly(L-glutamic hydrazide) as a carrier. Biochem. Pharmacol. 62:2001;1531-1536.
94. Hashida M., Akamatsu K., Nishikawa M., Yamashita F., Takakura Y. Design of polymeric prodrugs of prostaglandin E-1 having galactose residue for hepatocyte targeting. J. Control. Release. 62:1999;253-262.
95. Akamatsu K., Yamasaki Y., Nishikawa M., Takakura Y., Hashida M. Development of a hepatocyte-specific prostaglandin E-1 polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice. J. Pharmacol. Exp. Ther. 290:1999;1242-1249.
96. Gaál D., Hudecz F. Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide. Eur. J. Cancer. 34:1998;155-161.
97. Coessens V., Schacht E.H., Domurado D. Synthesis and in vitro stability of macromolecular prodrugs of norfloxacin. J. Control. Release. 47:1997;283-291.
98. Caiolfa V.R., Zamai M., Fiorino A., Frigerio E., Pellizzoni C., d'Argy R., Ghiglieri A., Castelli M.G., Farao M., Pesenti E. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Control. Release. 65:2000;105-119.
99. Duncan R., Coatsworth J.K., Burtles S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum. Exp. Toxicol. 17:1998;93-105.
100. Thomson A.H., Vasey P.A., Murray L.S., Cassidy J., Fraier D., Frigerio E., Twelves C. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br. J. Cancer. 81:1999;99-108.
101. Ohya Y., Kuroda H., Hirai K., Ouchi T. Synthesis and cytotoxic activity of conjugates of monomethoxy poly(ethylene-glycol) end-capped with doxorubicin via ester, amide, or Schiff-base bond. J. Bioact. Compat. Polym. 10:1995;51-66.
102. Ouchi T., Kuroda H., Ohya Y. Design of antitumor agent-terminated poly(ethylene glycol) conjugate as macromolecular prodrug. Acs. Ser. Symp. 680:1997;284-296.
103. Rodrigues P.C.A., Beyer U., Schumacher P., Roth T., Fiebig H.H., Unger C., Messori L., Orioli P., Paper D.H., Mulhaupt R., Kratz F. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg. Med. Chem. 7:1999;2517-2524.
104. Rodrigues P.C.A., Scheuermann K., Stockmar C., Maier G., Fiebig H.H., Unger C., Mulhaupt R., Kratz F. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 13:2003;355-360.
105. Nathan A., Zalipsky S., Kohn J. Strategies for covalent attachment of doxorubicin to poly(Peg-Lys), a new water-soluble poly(ether urethane). J. Bioact. Compat. Polym. 9:1994;239-251.
106. Pechar M., Ulbrich K., Jelínková M., Ří hová B. Enzymatically degradable PEG multiblock copolymers with hydrazone-attached doxorubicin in cancer therapy. 6th European Symposium on Controlled Drug Delivery, Noordwijkaan Zee (Neederlands). 2000;155-156. Abstract.
107. Pechar M., Ulbrich K., Jelínková M., Ří hová B. Enzymatically degradable PEG multiblock copolymers with hydrazone-attached doxorubicin in cancer therapy. J. Control. Release. 72:2001;253-254.
108. Ulbrich K., Etrych T., Chytil P., Jelínková M., Říhová B. Polymeric anticancer drugs with pH-controlled activation. 11th International Pharmaceutical Technology Symposium "Intelligent Drug Delivery Systems", Istanbul, Turkey. 2002;9-10. Proceedings.
109. Ulbrich K., Etrych T., Pechar M., Jelínková M., Říhová B. Novel generation of polymer-drug-carrier systems for site-specific therapy. 7th European Symposium on Controlled Drug Delivery Systems, Noordwijk aan Zee (Netherlands). 2002;13-15. Abstract.
110. Tomlinson R., Klee M., Garrett S., Heller J., Duncan R., Brocchini S. Pendent chain functionalized polyacetals that display pH-dependent degradation: a platform for the development of novel polymer therapeutics. Macromolecules. 35:2002;473-480.
111. Daussin F., Boschetti E., Delmotte F., Monsigny M. Para- benzylthiocarbamoyl-aspartyl-daunorubicin-substituted polytrisacryl - a new drug acid-labile arm-carrier conjugate. Eur. J. Biochem. 176:1988;625-628.
112. Chytrý V., Ulbrich K. Conjugate of doxorubicin with a thermosensitive polymer drug carrier. J. Bioact. Compat. Polym. 16:2001;427-440.
113. Sideratou Z., Tsiourvas D., Paleos C.M. Quaternized poly(propylene imine) dendrimers as novel pH-sensitive controlled-release systems. Langmuir. 16:2000;1766-1769.
114. Ihre H.R., De Jesus O.L.P., Szoka F.C., Frechet J.M.J. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug. Chem. 13:2002;443-452.
115. Yoo H.S., Lee E.A., Park T.G. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J. Control. Release. 82:2002;17-27.
116. Laguzza B.C., Nichols C.L., Briggs S.L., Cullinan G.J., Johnson D.A., Starling J.J., Baker A.L., Bumol T.F., Corvalan J.R.F. New antitumor monoclonal-antibody Vinca conjugates Ly203725 and related-compounds-design, preparation, and representative in vivo activity. J. Med. Chem. 32:1989;548-555.
117. Brusa P., Dosio F., Coppo S., Pacchioni D., Arpicco S., Crosasso P., Cattel L. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody. Farmaco. 52:1997;71-81.
118. Kaneko T., Willner D., Monkovic I., Knipe J.O., Braslawsky G.R., Greenfield R.S., Vyas D.M. New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjug. Chem. 2:1991;133-141.
119. Willner D., Trail P.A., Hofstead S.J., King H.D., Lasch S.J., Braslawsky G.R., Greenfield R.S., Kaneko T., Firestone R.A. (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 4:1993;521-527.
120. Greenfield R.S., Kaneko T., Daues A., Edson M.A., Fitzgerald K.A., Olech L.J., Grattan J.A., Spitalny G.L., Braslawsky G.R. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. 50:1990;6600-6607.
121. Braslawsky G.R., Edson M.A., Pearce W., Kaneko T., Greenfield R.S. Antitumor-activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor-cell killing. Cancer Res. 50:1990;6608-6614.
122. Braslawsky G.R., Kadow K.F., Knipe J., Mcgoff K., Edson M., Kaneko T., Greenfield R.S. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid-hydrolysis for antitumor-activity. Cancer Immunol. Immunother. 33:1991;367-374.
123. Trail P.A., Willner D., Knipe J., Henderson A.J., Lasch S.J., Zoeckler M.E., TrailSmith M.D., Doyle T.W., King H.D., Casazza A.M., Braslawsky G.R., Brown J., Hofstead S.J., Greenfield R.S., Firestone R.A., Mosure K., Kadow K.F., Yang M.B., Hellström K.E., Hellström I. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res. 57:1997;100-105.
124. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellström I., Hellström K.E. Cure of xenografted human carcinomas by Br96-doxorubicin immunoconjugates. Science. 261:1993;212-215.
125. Firestone R.A., Willner D., Hofstead S.J., King H.D., Kaneko T., Braslawsky G.R., Greenfield R.S., Trail P.A., Lasch S.J., Henderson A.J., Casazza A.M., Hellström I. Synthesis and antitumor activity of the immunoconjugate BR96-Dox. J. Control. Release. 39:1996;251-259.
126. Mueller B.M., Wrasidlo W.A., Reisfeld R.A. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjug. Chem. 1:1990;325-330.
127. Hudecz F., Ross H., Price M.R., Baldwin R.W. Immunoconjugate design: a predictive approach for coupling of daunomycin to monoclonal antibodies. Bioconjug. Chem. 1:1990;197-204.
128. Dillman R.O., Johnson D.E., Shawler D.L., Koziol J.A. Superiority of an acid-labile daunorubicin monoclonal antibody immunoconjugate compared to free drug. Cancer Res. 48:1988;6097-6102.
129. Yang H.M., Reisfeld R.A. Doxorubicin conjugated with a monoclonal-antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude-mice. Proc. Natl. Acad. Sci. USA. 85:1988;1189-1193.
130. Ding L., Yu L.Z., Xie S.S., Gong D.G., Vergidis R., Diener E. Application of target-specific drug immunoconjugates to experimental bone-marrow replacement therapy in mice. Cancer Res. 50:1990;1538-1543.
131. Wirth M., Fuchs A., Wolf M., Ertl B., Gabor F. Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells. Pharm. Res. 15:1998;1031-1037.
132. Wirth M., Kneuer C., Lehr C.M., Gabor F. Lectin-mediated drug delivery: discrimination between cytoadhesion and cytoinvasion and evidence for lysosomal accumulation of wheat germ agglutinin in the Caco-2 model. J. Drug Target. 10:2002;439-448.
133. Gabor F., Schwarzbauer A., Wirth M. Lectin-mediated drug delivery: binding and uptake of BSA-WGA conjugates using the Caco-2 model. Int. J. Pharm. 237:2002;227-239.
134. Wirth M., Gerhardt K., Warm C., Gabor F. Lectin-mediated drug delivery: influence of mucin on cytoadhesion of plant lectins in vitro. J. Control. Release. 79:2002;183-191.
135. Gabor F., Wirth M. Lectin-mediated drug delivery: fundamentals and perspectives. Stp Pharma Sci. 13:2003;3-16.
136. Haas M., Moolenaar F., Elsinga A., Van der Wouden E.A., De Jong P.E., Meijer D.K.F., De Zeeuw D. Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine combined with an absence of renal toxicity. J. Drug Target. 10:2002;81-89.
137. Patel V.F., Hardin J.N., Mastro J.M., Law K.L., Zimmermann J.L., Ehlhardt W.J., Woodland J.M., Starling J.J. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity. Bioconjug. Chem. 7:1996;497-510.
138. Patel V.F., Hardin J.N., Starling J.J., Mastro J.M. Novel trityl linked drug immunoconjugates for cancer-therapy. Bioorg. Med. Chem. Lett. 5:1995;507-512.
139. Patel V.F., Hardin J.N., Grindey G.B., Schultz R.M. Tritylated oncolytics as prodrugs. Bioorg. Med. Chem. Lett. 5:1995;513-518.
140. Srinivasachar K., Neville D.M. New protein cross-linking reagents that are cleaved by mild acid. Biochemistry. 28:1989;2501-2509.
141. Neville D.M., Srinivasachar K., Stone R., Scharff J. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria-toxin and toxin mutants. J. Biol. Chem. 264:1989;14653-14661.
142. Aboud-Pirak E., Hurwitz E., Bellot F., Schlessinger J., Sela M. Inhibition of human-tumor growth in nude-mice by a conjugate of doxorubicin with monoclonal-antibodies to epidermal growth-factor receptor. Proc. Natl. Acad. Sci. USA. 86:1989;3778-3781.
143. Brich Z., Ravel S., Kissel T., Fritsch J., Schoffmann A. Preparation and characterization of a water soluble dextran immunoconjugate of doxorubicin and the monoclonal antibody (ABL 364). J. Control. Release. 19:1992;245-257.
144. Zhu Z.P., Kralovec J., Ghose T., Mammen M. Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukemic B-cells with monoclonal-antibody adriamycin (doxorubicin) conjugates. Cancer Immunol. Immunother. 40:1995;257-267.
145. Noguchi A., Takahashi T., Yamaguchi T., Kitamura K., Takakura Y., Hashida M., Sezaki H. Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal-antibody and mitomycin C-dextran conjugate. Bioconjug. Chem. 3:1992;132-137.
146. Hovorka O., Štastný M., Etrych T., Šubr V., Strohalm J., Ulbrich K., Říhová B. Differences in the intracellular fate of free and polymer-bound doxorubicin. J. Control. Release. 80:2002;101-117.